Parabilis is a clinical-stage biopharmaceutical company developing Helicons, a class of stabilized alpha-helical peptides designed to reach and modulate intracellular protein targets. The company focuses on disease targets typically considered undruggable because they reside inside cells and present flat protein-protein interaction surfaces. Helicons are engineered to combine the cell-penetrating capabilities of small molecules with the high selectivity and precision of biologics. The company's lead product candidate, zolucatetide, is a clinical-stage therapy that blocks the interaction between β-catenin and TCF transcription factors to inhibit the Wnt/β-catenin signaling pathway. Parabilis is currently evaluating zolucatetide for the treatment of desmoid tumors, Familial Adenomatous Polyposis, and hepatocellular carcinoma. The company's pipeline also includes preclinical Helicon degraders targeting ERG for prostate cancer and the androgen receptor. Parabilis follows a specialty pharmaceutical business model, intending to self-commercialize its therapies for rare tumor indications in the U.S. Additionally, Parabilis enters into strategic collaborations, such as its partnership with Regeneron for Helicon-based antibody conjugates, to generate revenue through development milestones and royalties. Parabilis utilizes a discovery platform that integrates high-throughput screening and computational models to accelerate drug development.